Evidence map›Paper›PMID 26558786›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2015

The Transient Receptor Potential Melastatin 2 (TRPM2) Channel Contributes to β-Amyloid Oligomer-Related Neurotoxicity and Memory Impairment.

Valeriy G Ostapchenko, Megan Chen, Monica S Guzman, Yu-Feng Xie, Natalie Lavine, Jue Fan, Flavio H Beraldo, Amanda C Martyn, Jillian C Belrose, Yasuo Mori and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 1 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. TRP Channels in Excitotoxicity.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. TRP Channels in Stroke.Neuroscience bulletin · 2024
    Review
  16. Transient Receptor Potential Channels in the Healthy and Diseased Blood-Brain Barrier.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2024
    Review
  17. TRPM channels in health and disease.Nature reviews. Nephrology · 2024
    Review
  18. Review
  19. Review
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 4 countries.

Valeriy G OstapchenkoMolecular Medicine, Robarts Research Institute, Department of Physiology and Pharmacology, Schulich School of Medicine, and.ORCID http://orcid.org/0000-0002-3629-7702
Megan ChenMolecular Medicine, Robarts Research Institute.
Monica S GuzmanMolecular Medicine, Robarts Research Institute, Department of Physiology and Pharmacology, Schulich School of Medicine, and.
Yu-Feng XieDepartment of Pharmacology and Therapeutics, College of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 0T6, Canada, Neuroscience Research Group, Kleysen Institute for Advanced Medicine, University of Manitoba, Winnipeg, Manitoba R3E 3J7, Canada, and.
Natalie LavineDepartment of Pharmacology and Therapeutics, College of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 0T6, Canada, Neuroscience Research Group, Kleysen Institute for Advanced Medicine, University of Manitoba, Winnipeg, Manitoba R3E 3J7, Canada, and.
Jue FanMolecular Medicine, Robarts Research Institute.
Flavio H BeraldoMolecular Medicine, Robarts Research Institute.
Amanda C MartynMolecular Medicine, Robarts Research Institute.ORCID http://orcid.org/0000-0002-2760-3069
Jillian C BelroseMolecular Medicine, Robarts Research Institute.
Yasuo MoriLaboratory of Molecular Biology, Department of Synthetic Chemistry and Biological Chemistry, Graduate School of Engineering, Kyoto University, Kyoto 615-8510, Japan.
John F MacDonaldMolecular Medicine, Robarts Research Institute, Department of Physiology and Pharmacology, Schulich School of Medicine, and Department of Anatomy and Cell Biology, Schulich School of Medicine, University of Western Ontario, London, Ontario N6A 5B7, Canada.
Vania F PradoMolecular Medicine, Robarts Research Institute, Department of Physiology and Pharmacology, Schulich School of Medicine, and Department of Anatomy and Cell Biology, Schulich School of Medicine, University of Western Ontario, London, Ontario N6A 5B7, Canada, mprado@robarts.ca vprado@robarts.ca michael.jackson@umanitoba.ca.ORCID http://orcid.org/0000-0003-4994-6393
Marco A M PradoMolecular Medicine, Robarts Research Institute, Department of Physiology and Pharmacology, Schulich School of Medicine, and Department of Anatomy and Cell Biology, Schulich School of Medicine, University of Western Ontario, London, Ontario N6A 5B7, Canada, mprado@robarts.ca vprado@robarts.ca michael.jackson@umanitoba.ca.ORCID http://orcid.org/0000-0002-3028-5778
Michael F JacksonMolecular Medicine, Robarts Research Institute, Department of Physiology and Pharmacology, Schulich School of Medicine, and Department of Pharmacology and Therapeutics, College of Medicine, University of Manitoba, Winnipeg, Manitoba R3E 0T6, Canada, Neuroscience Research Group, Kleysen Institute for Advanced Medicine, University of Manitoba, Winnipeg, Manitoba R3E 3J7, Canada, and mprado@robarts.ca vprado@robarts.ca michael.jackson@umanitoba.ca.ORCID http://orcid.org/0000-0002-4730-201X
Molecular Medicine Research Institute · USUniversity of Manitoba · CAWestern University · CACzech Academy of Sciences, Institute of Physiology · CZKyoto University · JP

Funding

Canadian Institutes of Health Research MOP89919Canadian Institutes of Health Research MOP 93651Canadian Institutes of Health Research MOP-97771
6 · The paper itself

Abstract

In Alzheimer's disease, accumulation of soluble oligomers of β-amyloid peptide is known to be highly toxic, causing disturbances in synaptic activity and neuronal death. Multiple studies relate these effects to increased oxidative stress and aberrant activity of calcium-permeable cation channels leading to calcium imbalance. The transient receptor potential melastatin 2 (TRPM2) channel, a Ca(2+)-permeable nonselective cation channel activated by oxidative stress, has been implicated in neurodegenerative diseases, and more recently in amyloid-induced toxicity. Here we show that the function of TRPM2 is augmented by treatment of cultured neurons with β-amyloid oligomers. Aged APP/PS1 Alzheimer's mouse model showed increased levels of endoplasmic reticulum stress markers, protein disulfide isomerase and phosphorylated eukaryotic initiation factor 2α, as well as decreased levels of the presynaptic marker synaptophysin. Elimination of TRPM2 in APP/PS1 mice corrected these abnormal responses without affecting plaque burden. These effects of TRPM2 seem to be selective for β-amyloid toxicity, as ER stress responses to thapsigargin or tunicamycin in TRPM2(-/-) neurons was identical to that of wild-type neurons. Moreover, reduced microglial activation was observed in TRPM2(-/-)/APP/PS1 hippocampus compared with APP/PS1 mice. In addition, age-dependent spatial memory deficits in APP/PS1 mice were reversed in TRPM2(-/-)/APP/PS1 mice. These results reveal the importance of TRPM2 for β-amyloid neuronal toxicity, suggesting that TRPM2 activity could be potentially targeted to improve outcomes in Alzheimer's disease. SIGNIFICANCE STATEMENT: Transient receptor potential melastatin 2 (TRPM2) is an oxidative stress sensing calcium-permeable channel that is thought to contribute to calcium dysregulation associated with neurodegenerative diseases, including Alzheimer's disease. Here we show that oligomeric β-amyloid, the toxic peptide in Alzheimer's disease, facilitates TRPM2 channel activation. In mice designed to model Alzheimer's disease, genetic elimination of TRPM2 normalized deficits in synaptic markers in aged mice. Moreover, the absence of TRPM2 improved age-dependent spatial memory deficits observed in Alzheimer's mice. Our results reveal the importance of TRPM2 for neuronal toxicity and memory impairments in an Alzheimer's mouse model and suggest that TRPM2 could be targeted for the development of therapeutic agents effective in the treatment of dementia.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsCells, CulturedHumansMaleMemory DisordersMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicPlaque, AmyloidTRPM Cation ChannelsAmyloid beta-PeptidesTRPM2 protein, mouseTRPM Cation ChannelsAlzheimer's diseasecognitive impairmentmouse modelneurotoxicityTRPM2β-amyloid

Identifiers

PMID26558786
PMCPMC6605355
OpenAlexW2223781517

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.